Pfizer, Astellas Padcev combo shows overall survival benefit in urothelial cancer

by
Contributor since / Followers
1 month ago
Urinary bladder cancer with organs and tumors or cancerous cells 3D rendering illustration with male body. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.

libre de droit

  • A combination of Pfizer (NYSE:PFE) and Astellas’ (OTCPK:ALPMF)(OTCPK:ALPMY) antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) with Merck’s (MRK) Keytruda (pembrolizumab) demonstrated a sustained overall survival and progression-free survival benefit as a first-line therapy for urothelial cancer.
  • Data showed that Padcev + Keytruda reduced the
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *